Q1 2027 PetVivo Holdings Inc Earnings Call Transcript
Key Points
- Revenue increased 13% year-over-year and 33% sequentially, driven by a stronger sales team and focus on the flagship Spryng product.
- Gross margin improved to 66% from 63% in the prior year, with expectations for higher margins as the company shifts fully to its proprietary products.
- Net loss improved by 30% year-over-year, and cash used in operating activities decreased by 40%, reflecting better cost management.
- The acquisition of PiezoBioMembrane (PBM) is expected to close soon, adding a strong IP portfolio and opening opportunities for government grants and R&D tax credits.
- PetVivo.ai, the AI-powered veterinary platform, has demonstrated a 50-90% reduction in customer acquisition costs and 97% diagnostic accuracy, with a commercial launch expected soon.
- Health Canada recognized Spryng as a veterinary medical device, enabling entry into the Canadian market, which is projected to exceed $4.4 billion by 2031.
- The company has expanded its sales team and is building a distributor network in Canada, positioning for growth in new markets.
- Cash position is low at $123,000, and the company relies on an investor's remaining subscription commitment of $1.35 million to improve liquidity.
- The PBM acquisition is not yet closed, and the required capital raise of $5 million is not fully secured, creating uncertainty.
- R&D expenses decreased by 31% in the quarter, which may slow the development of new products and clinical studies.
- The company's gross margin was negatively impacted by the discontinued VetStem product line, which still accounted for 40% of sales in the quarter.
- The company faces significant capital needs for future clinical studies and product development, with no clear budget or funding plan disclosed.
- The success of PetVivo.ai and other new products is still unproven, with beta testing ongoing and no guarantee of market adoption.
- The company's reliance on government grants and partnerships introduces execution risks, as grant decisions are pending and partnerships may not yield expected results.
Good afternoon, everyone. Thank you for joining us today to discuss the results for the first quarter of our fiscal year ended June 30, 2026 -- sorry, it's for our fiscal quarter ended June 30, 2026. Hosting the call today is our Chief Executive Officer, John Lai; and our Chief Financial Officer, Garry Lowenthal; as well as myself, John Dolan, PetVivo's Chief Business Development Officer and General Counsel.
Following our remarks, we'll open the call for your questions. Then before we conclude today's call, I will provide some important cautions regarding the forward-looking statements made during the call, such as regarding our company's plans, expectations, objectives and anticipated results.
If you are connected to the call via your browser, please also review our safe harbor statements that are on the screen right now. I will give you a few seconds to take a look at these statements. I would also like to remind everyone that the call is being recorded in order to
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
